Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18359423 | 1.00 | CTSK (0.46) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL20182351 | 0.91 | CTSK (0.49) | CTSKCTSSTSHRITGB3ITGA2B | |
| SCHEMBL20163855 | 0.88 | CTSK (0.43) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL18359484 | 0.88 | CTSK (0.43) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL18368260 | 0.85 | CTSK (0.45) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL22683007 | 0.85 | PIK3CD (0.42) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL18359411 | 0.85 | PIK3CD (0.42) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL14751034 | 0.85 | CTSK (0.47) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL20163918 | 0.83 | CTSK (0.43) | CTSKCTSSTSHRKMT2AITGB3 | |
| SCHEMBL18359395 | 0.83 | CTSK (0.43) | CTSKCTSSTSHRKMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313397-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10221178-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180141947-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-9248942-B2 | Liquid phase epoxidation process | SOUTH BANK UNIVERSITY ENTERPRISES LTD. (GB) | 2016-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221178-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | CTSK 1442/4885CTSS 3381/4885TSHR 3466/4885 |
| US-20180141947-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | CTSK 1442/4885CTSS 3381/4885TSHR 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.